Nevada hearing considers expanding Medicaid to cover obesity treatments for children and adults

Senators on the Nevada Senate Committee on Health and Human Services on Tuesday heard testimony on Senate Bill 244, which would require Nevada Medicaid to cover intensive health behavior and lifestyle treatment for obesity, at least one FDA‑approved anti‑obesity medication, bariatric surgery consistent with specialty society guidelines and the CDC’s Diabetes Prevention Program for eligible adults.

Senator Roberta Lang, sponsor of SB 244, said the bill responds to rising obesity rates and the related burden of chronic disease among Medicaid enrollees. "Obesity continues to be one of the most challenging health problems we face, both as a state and as a nation," Lang said in opening remarks.

Dr. Steven Shane, a pediatrician who runs the Healthy Lifestyles Clinic at Renown Children’s Hospital in Reno, told the committee he regularly cannot offer evidence‑based therapies to his Medicaid patients because those services are not covered. "My patients suffer with a lower quality of life and with many other associated conditions like depression, low self‑esteem, diabetes, liver disease, high blood pressure, and high cholesterol," Dr. Shane said. He described the bill’s proposed coverage as including multi‑disciplinary lifestyle programs, medications for chronic weight management approved by the U.S. Food and Drug Administration and surgical interventions recommended by the American Society for Metabolic and Bariatric Surgery and the International Federation for Surgery for Obesity and Metabolic Disorders.

Supporters from professional and public‑health groups urged the committee to adopt the proposal. Carissa Pierce of the Children’s Advocacy Alliance said nearly half of Nevada children are enrolled in Medicaid and that expanded coverage could help prevent comorbidities and improve mental health outcomes. Dr. Terrence McAllister, president of the Nevada chapter of the American Academy of Pediatrics, said obesity is ‘‘a serious chronic illness’’ and called for a multifaceted approach. Bradley Mayer of the Southern Nevada Health District highlighted county data showing elevated childhood obesity rates in Clark and Washoe counties and said coverage could be cost‑effective by reducing future chronic disease costs.

Opponents raised cost and safety concerns. Barry Johnson, a Las Vegas resident who spoke in opposition, argued that medications could balloon Medicaid costs and raised concerns about side effects and pharmaceutical industry influence. A representative for Novo Nordisk testified in neutral and explained the amendment before the committee was meant to ensure patients had access to at least one FDA‑approved medication as part of a treatment plan.

Committee members pressed witnesses on program design and safeguards. Senator Titus asked whether pediatric surgical providers exist in statewide networks; witnesses said pediatric bariatric surgery is available in Nevada but procedures in adolescents are rare. Senators asked how utilization would be controlled and whether the state should add criteria or require adherence to clinical practice guidelines; Dr. Shane said guidelines can be referenced and that state formulary decisions could allow a small set of covered medications initially.

Supporters cited cost‑offset estimates and utilization data from other states: witnesses noted low current utilization among eligible Medicaid enrollees in states that cover anti‑obesity drugs and cited a study estimating modest per‑member per‑month state costs when medications were added to formularies, after accounting for health‑care savings. Dr. Shane described intensive lifestyle treatment dosing recommendations from pediatric and adult guideline bodies and noted Nevada Medicaid’s current limit of four hours of nutrition therapy over 12 months.

The committee did not take a final vote on SB 244 during the hearing. The bill sponsor and witnesses said they will continue to work on implementation details and guardrails for prescribing and surgical eligibility.

How this matters: The bill would change Medicaid coverage policy for a set of treatments that clinicians say can reduce long‑term costs from obesity‑related illness; opponents emphasized fiscal and safety concerns and urged stricter controls on medication access and pricing.

Details that were clarified in testimony: Nevada Medicaid currently covers Wegovy for adults only with established cardiovascular disease; Nevada Medicaid’s coverage for bariatric surgery is limited to those 21 and older with severe obesity and a complication; the CDC diabetes prevention program is not currently covered by Nevada Medicaid; specialty society guidelines were cited for surgical eligibility.

Looking ahead: Witnesses and the sponsor said they would refine statutory language and consider references to clinical practice guidelines and implementation timelines before the bill moves forward.